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Background: Intrapleural recombinant tissue plasminogen activator (r-TPA) has been successfully
evaluated in pediatric patientswith complicated parapneumonic pleural effusion (CPE) and pleural
empyema (PE). Yet, there is no data concerning r-TPA in adults with CPE/PE. The aim of our study
was to investigate the efficacy and complications of r-TPA in adult patients with CPE/PE.
Methods: Twenty consecutive patients (mean age 50 18.9 years) with pleural infection (14 CPE
and 6 PE) were included. Chest tube was inserted under guidance of chest ultrasound and/or
computed tomography. After failure of pleural fluid drainage, 25 mg of r-TPA was administered in-
trapleurally in a single dailydose.Theevaluationwasmadeaccording to imaging and clinical status.
Results: The mean volume of fluid increased significantly after r-TPA administration (p< 0.0001).
White blood cells count (WBC) and C-reactive protein (CRP) were significantly improved after
r-TPA instillations (both p< 0.0001). Significant clinical and imaging improvement was noted in
all but one patient after r-TPA administration (overall p< 0.0001). Complications observed were
mild: pain in 4 (25%) and local bleeding in 3 (15%) patients. Themedian number of r-TPA instillations
was 3 (range 2e5).
Conclusion: Intrapleural instillation of r-TPA at a dose of 25 mg is a well-tolerated and effective
treatment in 95% of our adult patients with CPE/PE.
ª 2008 Elsevier Ltd. All rights reserved.nt of Pneumonology, University Hospital of Alexandroupolis, 68100 Alexandroupolis, Greece.
.gr (M.E. Froudarakis).
8 Elsevier Ltd. All rights reserved.
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Pleural infection is a frequent clinical problem with high
morbidity and mortality. Mortality in western countries is
about 15%, while up to 40% undergo surgical drainage,
either video assisted and/or thoracotomy, with pleural
decortication.1,2 The goal of pleural infection therapy is to
heal the patient, to reduce mortality and morbidity, the
overall hospital stay and the need of surgical drainage and
pleural debridement. Animal models of experimentally
induced pleural infection have shown that fibrin deposition
occurs soon after bacterial infection,3 suggesting that early
intervention with fibrinolytics could potentially limit addi-
tional adhesion and loculation of the pleural fluid.4
The use of fibrinolytics to promote pleural drainage in
patients with parapneumonic effusions and empyema (PPE/
PE) is under debate.4 Case series and small controlled trials
investigating the intrapleural administration of fibrino-
lytics, such as urokinase and streptokinase, proved efficacy
in pleural fluid drainage and a significant reduction in the
need for surgery.5e7 A large British multicenter trial,
randomized patients with pleural infection to simple chest
tube drainage with or without administration of streptoki-
nase through the chest tube, demonstrated the lack of
effectiveness in reducing mortality, the need for surgical
drainage, or the length of the hospital stay.8 Yet, the
results of this trial are controversial, as patients were
included in both groups without the use of chest ultrasound
or computed tomography to localize the pleural fluid.9,10
Recombinant tissue plasminogen activator (r-TPA) has
been evaluated in pediatric patients with pleural infection
suggesting that r-TPA may be a more appropriate thera-
peutic agent.11e13 The pathogenesis of fibrin deposition in
exudative pleural effusions includes alterations in the
balance of procoagulant and fibrinolytic activity. This may
be secondary to a decreased level of endogenous r-TPA in
pleural fluid or because of inhibition of plasminogen and
plasmin by plasminogen activator inhibitors-1 and -2 and
other mediators.14,15 r-TPA breaks up the fibrinous debris,
thereby allowing drainage of the fluid.
However, no data exist concerning the efficacy and side
effects of intrapleural r-TPA administration in adult patients
with PPE/PE. Thus, the aim of our study was to investigate
prospectively the efficacy and complications of r-TPA in
a series of adult patients with complicated parapneumonic
pleural effusions (CPE) and/or pleural empyema (PE).
Patients and methods
Patients
Between February 2005 and August 2007, 20 consecutive
patients admitted to our department with pleural infection
(14 with CPE and 6 with PE), received intrapleural r-TPA
after failure of simple chest tube drainage (Table 1). All
patients were included to this phase II prospective study
after informed consent. The protocol was approved by the
Internal Board Review of our institution. All patients were
followed for at least 6 months by clinical examination,
chest radiography, chest ultrasound (US) and/or chest
computed tomography (CT).Parapneumonic effusion was defined as an effusion
associated with bacterial pneumonia.16 Patients with CPE
had a multiloculated effusion confirmed by US and/or CT,
which did not resolve with a single tube thoracostomy
placed in the largest loculation only after guidance by the
chest imaging (Fig. 1A). In all patients a systematic inves-
tigation for bacteria was undertaken with pleural fluid
smear gram stain and culture and blood culture. Patients
with PE had pus on thoracentesis, or positive smear or
pleural fluid cultures for bacteria and concomitant pneu-
monia, irrespective of the number of white blood cells in
the pleural fluid.1,16 Inclusion criteria for the protocol
were: multiloculated pleural effusion confirmed by chest
US and/or CT; and failure of drainage via thoracostomy
(<70 mL for the last 24 h), after intrapleural instillation of
100 mL of normal saline and after assurance that tube
clogging, kinking or improper positioning was excluded.
Multiloculations were defined as obvious septations seen on
chest US and/or CT, or air-fluid levels in the pleura seen on
chest radiography. Exclusion criteria were: the presence of
florid sepsis; bronchopleural fistula; and contraindication to
thrombolytic therapy, such as history of haemorrhagic
stroke, intracranial neoplasm, cranial surgery or head
trauma within 14 days, or major thoracic or abdominal
surgery within 10 days.4
r-TPA instillation
Closed intercostal drainage was carried out with a 24e32 Fr
chest tube attached to a water-sealed system under chest
US or CT guidance. Drainage from the chest tube was
recorded every 8 h. r-TPA (Actilyse Boehringer Ingelheim,
Athens Greece) was administered intrapleurally on a daily
basis, as a solution of 25 U in 100 mL of 0.9% saline solution
via the chest tube using a syringe and a 21-gauge needle.
The tube was subsequently clamped for 4 h and the patient
was rotated in various positions to disperse the drug.
Subsequently, the chest tube was opened to suction. The
interval time from the chest tube placement to initiation of
actilyse administration ranged 1e5 days. r-TPA was rein-
stilled, if on repeat chest US persistent pleural effusion was
found 24 h after the previous instillation. Before starting r-
TPA, we instilled intrapleurally 100 mL of normal saline to
avoid any volume effect due to instillation and to serve as
a control.
Assessment
The effectiveness of our protocol was assessed by the
clinical outcome (reduction in fever, in white blood cell
count (WBC), and C-reactive protein (CRP), the volume of
fluid drained from the chest tube daily, the chest radiog-
raphy and serial chest US and/or CT (Fig. 1B)). An unfa-
vorable response was defined by the persistent or
worsening symptoms, and no improvement or worsening in
the imaging, manifested by increase in pleural fluid volume
or appearance of new air-fluid levels. Decision to continue
r-TPA instillation or to proceed to surgical drainage was
taken by the attending pneumonologist and thoracic
surgeon on the basis of clinical judgement and signs of
sepsis. Chest tubes were removed after the net fluid
Table 1 Patients’ characteristics and interventional data
Gender Age Days of chest
tube drain age
Days of r-TPA
instillation
Volume before
r-TPA (ml)
Volume after
r-TPA (ml)
Pleural
pH
Pleural
LDH
(IU/L)
Pleural
protein
(gr/dl)
Pleural
glucose
(mgr/dl)
1 M 31 6 3 260 600 7.35 482 5.4 88
2 F 56 10 5 200 1400 7.08 1736 3.3 48
3 M 68 13 4 1500 5150 6.8 2792 5.3 5
4 M 17 8 3 550 1850 7.09 10008 4.5 22
5 F 24 6 4 210 1900 7.28 502 4.3 69
6 M 66 12 2 680 3400 6.84 782 4.5 10
7 M 62 13 4 375 2250 6.8 1482 5.6 21
8 F 50 10 2 400 3200 7.37 453 5.7 74
9 F 33 6 4 300 650 6.84 1764 4.9 49
10 M 52 5 2 650 1280 7.29 1412 4.6 86
11 M 57 5 4 250 2130 7.17 398 4.6 80
12 M 76 6 3 80 900 7.06 1730 5.0 37
13 M 25 14 5 2300 4300 7.39 510 4.6 70
14 M 27 6 2 300 2000 7.20 1106 4.3 10
15 F 54 7 2 200 2100 7.10 1380 4.5 20
16 M 82 7 2 200 1160 7.32 611 5.2 37
17 M 52 8 3 100 950 e e e e
18 M 70 18 4 1700 4500 7.16 550 4.3 36
19 M 62 7 2 500 2050 6.80 5391 4.4 10
20 M 36 8 3 700 2500 7.20 1323 4.6 22
Mean 50 8.8 3.1 572 2213 7.11 2811 4.71 42
SD 18.9 3.4 1 588 1297 0.20 2300 0.56 22
Abbreviations: M: male, F: female, and SD: standard deviation.
Figure 1 Chest CT scan of patient #15 with CPE; (A) just
before the tube insertion (Dec 16, 2006) and, (B) after r-TPA
last instillation (Dec 26, 2006).
1696 M.E. Froudarakis et al.drainage was less than 50 mL in 24 h. Haematological
studies included determination of haemoglobin, platelet
count, prothrombin time, activated partial thromboplastin
time, and levels of fibrinogen. All blood samples were taken
very early in the morning everyday (before the r-TPA
instillation) during patient’s hospitalization.
Radiographic improvement was evaluated by 2 inde-
pendent physicians. The last chest radiograph prior to
r-TPA initiation and the chest X-ray (CXR) taken at the
end of the r-TPA administration were evaluated. The
assessment of CXR used the estimated overall percentage
of shadowing present in the hemithorax.7 If there was
interobserver disagreement on scoring, the lower score
was recorded. Serial chest US evaluation was made by an
experienced operator for the presence of persistent
loculations.
The volume of pleural fluid drained from the chest tube
was recorded daily as well as the total solution instilled in
the pleural cavity. Body temperature was recorded every
3 h and the maximum measurements prior and after acti-
lyse administration were compared.
Statistical analysis
All values are expressed as mean standard deviation
(SD). Comparison of means between groups was per-
formed with the Student’s t-test. A p-value of less than
0.05 was considered significant. We used a statistical
software package (StatView, version 4.5; Abacus
Concepts Inc., Berkeley CA, USA.) for the evaluation of
our data.
Figure 3 Mean values (SD) of CRP (mg/dL), before and
after r-TPA instillation (p< 0.0001).
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Clinical improvement in terms of fever, dyspnea, and
discomfort was noted after the end of the course of r-TPA in
all but one patient (patient #9, Table 1). This patient
underwent VATS decortication after 4 days of r-TPA instil-
lation due to unfavorable outcome with worsening symp-
toms (fever, chills, dyspnea), persistence of elevated WBC
and CRP, although initial improvement was noted with
minimal CXR improvement but persistent loculation on
chest US. On surgical exploration, a stage III pleural
empyema (organizing stage) was found, and an empye-
mectomy was performed. The patient was discharged after
a total hospitalization of 21 days. Her CXR was clear at 6
months from initial admission (Table 1).
In 7 cases (35%) a microbiological diagnosis was estab-
lished, from pleural fluid (5 cases) and blood cultures (2
cases). In all cases a Streptococcus pneumoniae was iden-
tified. Nine patients (45%) had received prior oral antibiotic
therapy prescribed by their physician 1e7 days before
admission. Eleven patients (55%) have been addressed to
our department from another institution for failure of
initial treatment. Seven patients presented with CPE and 6
patients with empyema (patients #3, #6, #7, #9, #17, #19).
The mean duration of fever before r-TPA instillation was
8.5 4.6 days and 2.8 2 days after r-TPA initialisation
(pZ 0.0044). Inflammatory parameters measured
decreased significantly after r-TPA instillation. Thus, the
mean value (SD) of WBC before r-TPA instillation was
14,043 5126 per mm3 and 6458 1862 per mm3 after
r-TPA instillation (Fig. 2, p< 0.0001). The mean (SD) value
of CRP (reference value< 3 mg/dL) before r-TPA instilla-
tion was 12.64 5.2 mg/dL, and 3.15 2.91 mg/dL after
r-TPA instillation (Fig. 3, p< 0.0001).
The total drainage before the use of r-TPA ranged from
80 to 2300 mL with a mean (SD) of 572 588 mL. The
mean (SD) net total fluid drained after r-TPA instillation
was 2213 1297 mL (range 600e5150). This increase in
total mean pleural fluid was significant (p< 0.0001) (Fig. 4).
The number of r-TPA instillations ranged from 2 to 5
(mean SD: 3.1 1). No significant difference in theFigure 2 Mean values (SD) of WBC (per mm3), before and
after r-TPA instillation (p< 0.0001).drained fluid was observed before and after normal saline
instillation.
Overall, the mean occupation of the chest X-ray by the
pleural effusion was 79 23% before r-TPA administration.
This occupation was significantly improved after r-TPA
administration, becoming 18 17%, as well as after one
month from discharge (Fig. 5). Specifically, 19 patients have
considerably improved their chest CXR after r-TPA admin-
istration: 13 patients had a residual effusion on chest X-ray
(shadow< 10% of hemithorax) and 6 patients presented
a score of 30% on chest X-ray. From those 6 patients with
30% score, 4 of them had initially a complete (100%) hem-
ithorax occupation, and the remaining 2 had initially 75%
score. The only patient who did not improve CXR was the
patient with treatment failure who underwent VATS
(patient #9). During the follow-up, all but 5 patients had
a clear CXR at one month. Three of those 5 patients still had
a pleural thickening at 3 months which was totally
regressed at 6 months, while the patient #9 still had
a residual effusion at 6 months. The overall success rate for
r-TPA treatment was 95%.
The total hospital stay was 18.64 7.3 days and the
overall chest tube drainage in our department was 8.8 3.5
days. All patients tolerated well the drainage procedures
and instillation of r-TPA. Adverse reactions after r-TPAFigure 4 Total mean volume (SD) of pleural fluid drainage
(mL), before and after r-TPA instillation (p< 0.0001).
Figure 5 Mean occupation (%) of the chest X-ray before,
after and at one month from r-TPA instillation (overall
p< 0.0001).
1698 M.E. Froudarakis et al.administration, were mild and did not affect the r-TPA
administration, including pain during instillation in 4
patients (25%) and mild local hemorrhage in 3 patients
(15%). No significant changes in the coagulation profile of
the patients were observed, including the patients who
presented pleural hemorrhage after r-TPA administration.
All patients successfully treated with r-TPA had no recur-
rences and were doing well at follow-up.
Discussion
This is the first prospective study in adult patients with CPE
and PE of intrapleural administration of r-TPA through
a chest tube with successful treatment. The success rate in
our study was 95%. The amount of the pleural fluid drained
was significantly improved after r-TPA instillation, resulting
in a significant improvement of the chest X-ray. Also, we
noted a rapid and significant decrease of inflammatory
parameters such as WBC and CRP, after intrapleural
administration of r-TPA. This benefit was achieved without
systemic fibrinolysis and/or local or systemic hemorrhage.
The overall hospital stay and pleural drainage of our
patients was comparable to studies published with other
fibrinolytics.
During the last 10 years, several studies (Table 2) have
documented the successful resolution of parapneumonic
effusions, using intrapleural streptokinase or urokinase and
standard, large-sized thoracostomy tubes to facilitate
pleural drainage.5e7,17 Success rate of intrapleural strep-
tokinase in pleural infections is ranging from 82 to
100%,5,7,17 comparable to the urokinase18 (Table 2). In
those studies a significant improvement of the amount of
pleural fluid was reported, after intrapleural instillation of
fibrinolytics, comparable to our study, with a significant
improvement of CXR. The patients had a mean hospital stay
and mean pleural drainage comparable to those of our
study (Table 2). This is interesting considering that 55% of
our patients were addressed to our teaching hospital for
failure of initial treatment, which increased considerably
the overall hospital stay. Also, the inflammatory parame-
ters assessed have been improved as quickly as in our study.Studies with r-TPA in pleural infections report minor side
effects even in the very young age.11e13 Ray et al11 repor-
ted a series of 6 children with pleural infection with
a success rate of 100%. They had a significant improvement
in chest X-ray and in pleural drainage, while hospital stay
was low.11 Weinstein et al12 conducted an observational
cohort study in children with pleural infection over a 6-year
period: 12 children received early r-TPA (within 24 h of
diagnosis), 18 children received late r-TPA (>24 h after
diagnosis), and 23 children had thoracostomy tube drainage
alone. Early instillation of r-TPA showed improvement in
the duration of chest tube and in the rate of pleural fluid
drainage.12 In a retrospective analysis of 71 children with
CPE or empyema Wells and Haven13 noted a similar accu-
racy for r-TPA and urokinase (98% versus 100%) with also
a significant improvement in pleural fluid drainage for r-TPA
comparing to urokinase. Considering also that patients with
r-TPA had lower days of chest tube drainage and lower days
of fibrinolytic therapy, the authors concluded that r-TPA
produced greater thoracostomy tube output than that of
urokinase.13
Gates et al reviewed the data from 54 children treated
for pleural infection.19 According to the treatment they
classified their patients in IV groups: group I (nZ 17)
pleural drainage only, group II (nZ 24) chest tube drainage
and instillations of r-TPA, group III (nZ 5) chest tube
drainage, instillations of r-TPA and VATS, and group IV
(nZ 6) VATS only. They found that children in group II had
significantly lower duration of hospitalization and chest
tube drainage comparing to those in group III and IV, but no
difference comparing to those in group I. Important limi-
tations of the study to draw conclusions are the small
number of patients analyzed in groups III and IV, the fact
that the group III patients are the patients who arbitrarily
failed the group II treatment 48 h after initiation, and the
retrospective nature of the study.19
However, many questions are still pending concerning
the use of fibrinolytics in CPE and empyema. As studies
include patients with CPE and empyema,8 it is difficult to
evaluate whether patients with CPE are more likely to
benefit from the fibrinolytic therapy, while patients with
empyema are not.10,20 The use of the right caliber of chest
tube1 to put in the larger loculation under chest US and/or
CT guidance is under investigation.9,10 Consensus on stan-
dard dosing and duration of treatment are also lacking. The
place of fibrinolytics as compared to minimal invasive
techniques such as thoracoscopy is another issue.21,22 Well-
controlled studies stratifying patients according to the
stage of pleural infection must be performed in order to
answer those questions.
A study performed in Britain8 randomizing patients with
pleural infection either to receive intrapleural streptoki-
nase or placebo has multiple methodological problems: the
chest tube drainage was placed without image guidance,
referral to surgery was not based in criteria, but was left to
the judgement of the individual clinician, who was not
always a respiratory physician. The only patient in our
study (patient #9) addressed for surgical treatment was
based on presence of clinical and laboratory findings in
favor of persistent sepsis, despite accurate therapy. The
need for surgery of radiographic improvement in the
absence of sepsis is arbitrary.23 Also, streptokinase is
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r-TPA in pleural infections 1699probably inferior to urokinase18,24 and r-TPA for intra-
pleural use in pleural infection. We placed our tube under
chest US or CT in all 20 patients, which is important for
accurate drainage. Immunization with streptokinase is
another important issue. It causes fever onset, allergic
reactions8 and may be the cause of treatment failure,
which is not the case of urokinase18 or r-TPA.
Complications in our study were minor including mild
local bleeding in 3 patients, and pain in 4 after r-TPA
administration. Authors also reported these complications
by using intrapleural r-TPA in pediatric patients.11,12
However, Weinstein et al in their series of 30 children did
not observe any local bleeding.12 All authors agree that in
no case the occurrence of such complications affected the
dose of r-TPA instilled intrapleurally.11,13 Primary areas of
concern of the use of both streptokinase and urokinase in
pleural infections are bleeding and the potential to open
bronchopleural fistulas.8,24,25 Coagulation studies have
shown that fibrinolytic agents have limited systemic fibri-
nolytic effect.8,17,26,27 This is due to the doses used for
intrapleural fibrinolysis (as well as the fact that there is no
direct vascular injection) are small compared with those
used for direct intra-vascular therapy. Therefore, a possible
explanation of a mild pleural hemorrhage, may be the lysis
of loculations and/or the traumatisms caused by the chest
tube manipulations.
The lack of serious adverse events in our series, associ-
ated with intrapleural r-TPA is important, particularly in
view of the concerns related to the safety of streptokinase
and urokinase. Furthermore, there are biologically plau-
sible reasons that r-TPA may be preferred as a fibrinolytic
agent. It has been shown that in parapneumonic pleural
fluid, there is an imbalance of fibrinolytic and procoagulant
activity because of a reduction of endogenous tissue plas-
minogen activator and the presence of plasminogen acti-
vator inhibitors.28,29
This study suggests that r-TPA improve chest tube
drainage of CPE and that intrapleural fibrinolysis with r-TPA
is a safe and effective method for treating adults with
parapneumonic effusion or empyema. A multicenter
randomized controlled trial is needed to investigate the
place of intrapleural r-TPA in the management of CPE and
empyema.
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